The estimated Net Worth of Paul L Berns is at least $4.55 Million dollars as of 5 August 2021. Mr. Berns owns over 1,450 units of Jazz Pharmaceuticals plc stock worth over $871,528 and over the last 14 years he sold JAZZ stock worth over $3,141,780. In addition, he makes $532,573 as Independent Director at Jazz Pharmaceuticals plc.
Sign up
Mr. Berns JAZZ stock SEC Form 4 insiders trading
Paul has made over 14 trades of the Jazz Pharmaceuticals plc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 1,450 units of JAZZ stock worth $223,300 on 5 August 2021.
The largest trade he's ever made was buying 117,371 units of Jazz Pharmaceuticals plc stock on 20 April 2016 worth over $248,827. On average, Paul trades about 6,426 units every 100 days since 2010. As of 5 August 2021 he still owns at least 8,290 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Mr. Berns stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Berns biography
Paul L. Berns serves as Independent Director of the Company. Mr. Berns is a venture partner at ARCH, a venture capital firm, and Executive Chair of BlackThorn Therapeutics, a clinical-stage, privately-held biopharmaceutical company, where he serves on the board of directors. He also currently serves as Chairman of the board of Epirium Bio, Inc., a clinical-stage, privately-held biopharmaceutical company, as well as on the board of directors of UNITY Biotechnology, Inc., a publicly-held biotechnology company. From March 2014 to June 2016, he served as the Chief Executive Officer and President of Anacor Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. in June 2016. He also served as a member of the board of directors of Anacor Pharmaceuticals, Inc. from 2012 until 2016, including as Chairman of its board of directors from 2013 until 2016. From September 2012 to March 2014, he was a self-employed consultant to the pharmaceutical industry. From March 2006 to September 2012, he served as President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc., a pharmaceutical company acquired by Spectrum Pharmaceuticals, Inc. From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns previously served on the boards of directors of Men
What is the salary of Paul Berns?
As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Paul Berns at Jazz Pharmaceuticals plc is $532,573. There are 19 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
How old is Paul Berns?
Paul Berns is 53, he's been the Independent Director of Jazz Pharmaceuticals plc since 2010. There are 17 older and 9 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
What's Paul Berns's mailing address?
Paul's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Jazz Pharmaceuticals plc
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright, and Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
What does Jazz Pharmaceuticals plc do?
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
What does Jazz Pharmaceuticals plc's logo look like?
Complete history of Mr. Berns stock trades at Cellectar Biosciences Inc, Jazz Pharmaceuticals plc, Menlo Therapeutics, and Unity Biotechnology Inc
Jazz Pharmaceuticals plc executives and stock owners
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:
-
Bruce Cozadd,
Chairman of the Board, Chief Executive Officer -
Daniel Swisher,
President, Chief Operating Officer -
Robert Iannone,
Executive Vice President, Research and Development -
Neena Patil,
Senior Vice President, General Counsel -
Bruce C. Cozadd,
Co-Founder, Chairman & CEO -
Daniel N. Swisher Jr.,
Pres -
Anne O'Riordan,
Independent Director -
Dr. Robert Iannone M.D.,
Exec. VP of R&D and Chief Medical Officer -
Renee D. Gala,
Exec. VP & CFO -
Kim Sablich,
Exec. VP & GM of North America -
Rick Winningham,
Independent Director -
Heather McSharry,
Independent Director -
Peter Gray,
Independent Director -
Norbert Riedel,
Independent Director -
Patrick Enright,
Independent Director -
Catherine Sohn,
Independent Director -
Elmar Schnee,
Independent Director -
Seamus Mulligan,
Independent Director -
Kenneth O'Keefe,
Independent Director -
Paul Berns,
Independent Director -
Diane Schrick,
Senior Director, Investor Relations -
Patricia Carr,
Vice President, Finance and Principal Accounting Officer -
Samantha Pearce,
Senior Vice President, Europe and Rest of World -
Finbar Larkin,
Senior Vice President - Technical Operations -
Kimberly Sablich,
Executive Vice President, General Manager - North America -
Renee Gala,
Chief Financial Officer, Executive Vice President -
Neena M. Patil J.D.,
Chief Legal Officer and Sr. VP of Legal & Corp. Affairs -
Andrea N. Flynn,
VP & Head of Investor Relations -
Dr. Finbar Larkin Ph.D.,
Sr. VP of Technical Operations -
Patricia Carr,
VP of Fin. & Principal Accounting Officer -
Christopher John Tovey,
Exec. VP, COO and MD of Europe & International -
Paul Treacy,
SVP, Technical Operations -
Suzanne Sawochka Hooper,
EVP and General Counsel -
Karen L. Smith,
Global Head of R&D and CMO -
Karen J Wilson,
VP of Finance & PAO -
Russell J. Cox,
SVP, Sales and Marketing -
Iain Mc Gill,
Head of EUSA Int'l & SVP -
Matthew P. Young,
SVP & CFO -
Michael Patrick Miller,
EVP, US Commercial -
Jennifer E. Cook,
Director -
Mark Douglas Smith,
Director -
Jp Llckkr Jp Iii Llckkr Iii...,
-
Bryan C Cressey,
Director -
Alan Sebulsky,
Director -
Kathryn E Falberg,
SVP and CFO -
Paul Egolkin Perryhuth Joha...,
-
Michael W Michelson,
Director -
Samuel D Colella,
Director -
Financial Holdings Iii, Llc...,
-
Group Holdings L.P.Kkr Grou...,
-
Matthew K Fust,
Senior Vice President & CFO -
Jeffrey K Tobias,
EVP, Research & Dev and CMO -
Fintan Keegan,
EVP, Technical Operations -
Cressey Equity Partners Inc...,
-
Mark G. Eller,
SVP, Research & Clinical Dev. -
James C Momtazee,
Director -
Jp Iii Llckkr Partners Iii,...,
-
Fund Holdings L.P.Kkr Jp Ll...,
-
Michael A. Des Jardin,
SVP, Product Development -
Nathaniel M Zilkha,
Director -
Joan Colligan,
Principal Accounting Officer -
Janne Lt Wissel,
Senior VP of Development -
James B Tananbaum,
Director -
Samuel R Saks,
Chief Executive Officer -
Robert M Myers,
President -
E Alexander Albert,
Director -
Jp Llckkr Jp Iii Llckkr Iii...,
-
Paul Ehuth Johannes Pfisher...,
-
Michael W Janetschek Willia...,
-
Carol A Gamble,
SVP, GC and Corporate Secty -
Management Llcmignone Rober...,
-
Henry Rroberts George Rgree...,
-
Michael Wkkr Financial Hold...,
-
Paul Ehuth Johannes Pfisher...,
-
Patel Jaimin,
Director -
Michael Wkkr Financial Hold...,
-
Kim Sablich,
EVP, GM of U.S. -
Mary Elizabeth Henderson,
SVP, Technical Operations -
Christopher J. Tovey,
EVP, COO & Managing Director E -
Laura Hamill,
Director -
Patrick Kennedy,
Director -
Philip L Johnson,
EVP & Chief Financial Officer